Product Description
Mechanisms of Action: ADORA2 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Acorda
Company Location: ARDSLEY NY 10502
Company CEO: Ron Cohen
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Parkinson's Disease
Phase 1: Healthy Volunteers|Hepatic Insufficiency|Cocaine-Related Disorders|Liver Failure
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03212313 |
TOZ-CL11 | P1 |
Terminated |
Liver Failure|Hepatic Insufficiency |
2017-12-31 |
17% |
2019-03-21 |
Treatments |
NCT03200080 |
TOZ-CL09 | P1 |
Terminated |
Healthy Volunteers |
2017-11-28 |
2019-03-21 |
Treatments |
|
NCT02240290 |
PD0026 | P1 |
Completed |
Healthy Volunteers |
2013-10-01 |
2019-03-20 |
Treatments |
|
NCT00783276 |
DA009262-14 | P1 |
Completed |
Cocaine-Related Disorders |
2013-01-01 |
2019-03-18 |
Treatments |
|
2011-005054-59 |
(none) | P2 |
Completed |
Parkinson's Disease |
2012-10-17 |
2022-03-13 |
Treatments |
|
NCT00605553 |
SYN115-CL01 | P2 |
Completed |
Parkinson's Disease |
2009-05-01 |
2019-03-18 |
Treatments |
|
2016-003961-25 |
2016-003961-25 | P3 |
Terminated |
Parkinson's Disease |
2020-06-30 |
2022-03-13 |
Treatments |
|
2014-005630-60 |
TOZ-PD | P3 |
Completed |
Parkinson's Disease |
2019-04-29 |
18% |
2022-03-13 |
Treatments |
NCT03051607 |
TOZ-CL06 | P3 |
Terminated |
Parkinson's Disease |
2018-01-16 |
20% |
2019-03-21 |
|
NCT02453386 |
TOZ-PD | P3 |
Terminated |
Parkinson's Disease |
2018-01-12 |
18% |
2019-03-20 |
Treatments |
NCT01283594 |
SYN115-CL02 | P3 |
Completed |
Parkinson's Disease |
2012-10-01 |
2019-03-19 |
Study Completion Date|Treatments |